XML 20 R9.htm IDEA: XBRL DOCUMENT v3.23.3
REVENUE
 9 Months Ended
Sep. 30, 2023
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
 
Disaggregated Revenue
 
The following table reflects total revenue, net for the three and nine months ended September 30, 2023 and 2022 (in thousands): 
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Product sales, net:
INDOCIN products$17,948$21,869 $76,369$66,067 
ROLVEDON7,132— 7,132— 
Otrexup2,807 3,004 9,222 8,699 
Sympazan2,103 — 7,232 — 
SPRIX2,545 2,455 6,807 6,437 
CAMBIA1,993 5,808 6,062 17,464 
Zipsor597 259 2,751 2,704 
Other products12 884 1,414 3,887 
Total product sales, net35,137 34,279 116,989 105,258 
Royalties and milestone revenue490 473 1,910 1,916 
Other revenue— (540)185 (1,290)
Total revenues$35,627 $34,212 $119,084 $105,884 
Product Sales, net

Product sales consists of sales of the Company’s products as listed above. As a result of the Spectrum Merger, the Company began recognizing ROLVEDON sales in August 2023. The Company acquired Sympazan and began shipping and recognizing its product sales in October 2022.

Other product sales include product sales for OXAYDO and SOLUMATRIX product.. The Company ceased OXAYDO product sales beginning in September 2023, and ceased SOLUMATRIX sales beginning in July 2022.

Royalties and Milestone Revenue

In November 2010, the Company entered into a license agreement granting the counterparty the rights to commercially market CAMBIA in Canada. The counterparty to the license agreement independently contracts with manufacturers to produce a specific CAMBIA formulation in Canada. The Company receives royalties on net sales on a quarterly basis as well as certain one-time contingent milestone payments upon the occurrence of certain events. The Company recognized revenue related to CAMBIA in Canada of $0.5 million and $1.5 million for the three and nine months ended September 30, 2023, respectively, and $0.5 million and $1.5 million for the three and nine months ended September 30, 2022, respectively.
The Company records contract liabilities in the form of deferred revenue resulting from prepayments from customers in Other current liabilities in the Company’s Condensed Consolidated Balance Sheets. As of September 30, 2023 and December 31, 2022, contract liabilities were zero and $0.2 million, respectively. The Company recognized Milestone revenue associated with the completion of certain service milestones of $0.5 million for both the nine months ended September 30, 2023 and 2022.
The Company recognized no Milestone revenue associated with the completion of certain service milestones for both the three months ended September 30, 2023 and 2022.
Other Revenue

Other revenue consists of sales adjustments for previously divested products, which includes adjustments to reserves for product sales allowances (gross-to-net sales allowances) and can result in a reduction to or an increase to total revenue during the period.